Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,4-Diallyloxybenzene SCHEMBL302448 | 0.84 | CA12 (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9711921 | 0.83 | SLC5A1 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL826483 | 0.83 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8418525 | 0.82 | ALDH1A1 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9712052 | 0.82 | SLC5A1 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9712151 | 0.82 | SLC5A1 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9504919 | 0.82 | BCHE (0.43) | CA12CA1CA9ALDH1A1MAPT | |
| SCHEMBL7929785 | 0.81 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7782792 | 0.81 | ALDH1A1 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6041660 | 0.81 | CA12 (0.49) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030103-B2 | Stable helical ionic polypeptides | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030103-B2 | Stable helical ionic polypeptides | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2646048-B1 | STABLE HELICAL IONIC POLYPEPTIDES | UNIV ILLINOIS (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2847199-B1 | PERMEABLE GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2847199-B1 | PERMEABLE GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9793456-B2 | Molded resin body for surface-mounted light-emitting device, manufacturing method thereof, and surface-mounted light-emitting device | KANEKA CORPORATION (JP) | 2017-10-17 | — | — | US | disclosed |
| US-9611275-B2 | Permeable glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS, INC. (CA) | 2017-04-04 | — | — | US | disclosed |
| US-9611275-B2 | Permeable glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS, INC. (CA) | 2017-04-04 | — | — | US | disclosed |
| US-9611275-B2 | Permeable glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS, INC. (CA) | 2017-04-04 | — | — | US | disclosed |
| US-9496468-B2 | Curable resin composition, curable resin composition tablet, molded body, semiconductor package, semiconductor component and light emitting diode | KANEKA CORPORATION (JP) | 2016-11-15 | — | — | US | disclosed |
| US-5091274-A | Modified polysiloxanes | NATIONAL SCIENCE COUNCIL (TW) | 1992-02-25 | — | — | US | disclosed |
| EP-0434840-A1 | ORGANIC POLYMER, PREPARATION THEREOF, AND CURABLE COMPOSITION COMPRISING SAME | Kanegafuchi Chemical Industry Co., Ltd. (JP) | 1991-07-03 | — | — | EP | disclosed |
| EP-0431173-A1 | CURING AGENT, METHOD OF PREPARATION THEREOF, AND CURABLE COMPOSITION PREPARED THEREFROM | Kanegafuchi Chemical Industry Co., Ltd. (JP) | 1991-06-12 | — | — | EP | disclosed |
| EP-0415404-A2 | Process for producing unsaturated group-terminated high-molecular weight polyalkylene oxide | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1991-03-06 | — | — | EP | disclosed |
| EP-0212838-B1 | OPTICALLY ACTIVE LIQUID CRYSTAL COMPOUND HAVING METHYLENEOXY GROUP AND COMPOSITION CONTAINING SAME | Chisso Corporation (JP) | 1990-10-03 | — | — | EP | disclosed |
| EP-0312967-A1 | Sealant for double-layered glass | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1989-04-26 | — | — | EP | disclosed |
| US-4729847-A | LIGHT SWITCHING ELEMENT | CHISSO CORPORATION (JP) | 1988-03-08 | — | — | US | disclosed |
| EP-0212838-A1 | Optically active liquid crystal compound having methyleneoxy group and composition containing same | Chisso Corporation (JP) | 1987-03-04 | — | — | EP | disclosed |
| US-4398944-A | N-ALKOXYPHENYLMETHYL-2-CHLOROACETAMIDE | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1983-08-16 | — | — | US | disclosed |
| US-4221919-A | Antiinflammatory substituted phenylacetic acids | SPOFA, UNITED PHARMACEUTICAL WORKS (CS) | 1980-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10030103-B2 | Stable helical ionic polypeptides | GHITM, SLC7A1, PICALM | CA12 155/4885CA1 163/4885CA2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.